## Edgar Filing: LABORATORY CORP OF AMERICA HOLDINGS - Form 8-K

### LABORATORY CORP OF AMERICA HOLDINGS

Form 8-K

November 28, 2001

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 November 28, 2001

-----

(Date of earliest event reported)

#### LABORATORY CORPORATION OF AMERICA HOLDINGS

\_\_\_\_\_

(Exact name of registrant as specified in its charter)

DELAWARE	1-11353	13-3757370
(State or other	(Commission	(IRS Employer
jurisdiction of	File Number)	Identification
incorporation)		Number)

358 SOUTH MAIN STREET, BURLINGTON, NORTH CAROLINA 27215

(Address of principal executive offices)

336-229-1127

-----

(Registrant's telephone number, including area code)

ITEM 9. Regulation FD Disclosure.

Laboratory Corporation of America -Registered Trademark-Holdings (LabCorp -Registered Trademark-) (NYSE:LH) announced that Bradford T. Smith, executive vice president of public affairs, is scheduled to speak at the SG Cowen Global Health Care Conference in Paris, France on Thursday, November 29 at 10:20 a.m. (4:20 a.m. EST). The presentation will be webcast live, with a rebroadcast available for a period of 90 days, and may be heard online at www.labcorp.com.

At the conference, Mr. Smith will reiterate Company guidance for 2001 and 2002, as filed in an 8K on October 22. Mr. Smith will state, "For 2001, we expect revenue growth of 13.5 percent, EBITDA margins of approximately 21 percent of sales and EPS growth of approximately 55 percent compared to 2000. For 2002, we expect to increase overall revenues by approximately 12 percent compared to 2001 and we expect EPS growth, as calculated under existing accounting rules, of

# Edgar Filing: LABORATORY CORP OF AMERICA HOLDINGS - Form 8-K

approximately 33 percent compared to 2001. In calculating earnings and EPS under the new accounting rules regarding goodwill, we expect the non-amortization of goodwill to have an impact of approximately \$26 million in 2002, resulting in an increase to EPS of approximately \$0.36."

Each of the above forward-looking statements is subject to change based on various important factors, including without limitation, competitive actions in the marketplace and adverse actions of governmental and other third-party payors. Further information on potential factors that could affect LabCorp's financial results is included in the Company's Form 10-K for the year ended December 31, 2000 and subsequent SEC filings.

#### SIGNATURES

Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

By:/s/ BRADFORD T. SMITH

-----

Bradford T. Smith Executive Vice President and Secretary

Date: November 28, 2001